资讯

There May Be Reason For Hope In GSK's (LON:GSK) Disappointing Earnings
LSE:GSK Earnings and Revenue History May 7th 2025 The Impact Of Unusual Items On Profit. For anyone who wants to understand ...
Down 20% over the year, is GSK’s share price a stunning bargain after its Q1 results?
GSK’s share price has fallen significantly in the past 12 months, but this could mean it looks a major bargain now, ...
来自MSN4 个月
GSK再赴进博之约，聚焦红斑狼疮，助患者“破茧·橙蝶”
为帮助更多患者身心纾困，11月7日，澎湃新闻发起、葛兰素史克（GSK）中国公益支持的“破茧·橙蝶”红斑狼疮公益项目，在第七届中国国际进口 ...
Wall Street Journal7 天
GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs
GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market ...
Nature5 年
Could your science and technology accelerate vaccine research?
GSK is building on these advances by using reverse vaccinology, innovative trial designs and other techniques to accelerate vaccine discovery and development. Effectively harnessed, GSK believes ...
pharmaphorum3 天
Next stage in GSK’s Zantac defense gets underway today
The three-day hearing comes a few months after GSK decided to settle a complaint ... called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.
pharmaphorum2 天
GSK says $2.2bn settlement resolves most Zantac litigation
as well as other ranitidine products sold by other companies – increased the risk of cancer. GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence ...
STAT20 天
GSK blood cancer therapy, once pulled from the market, is approved in the U.K.
under the approval from the Medicines and Healthcare products Regulatory Agency. Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from ...